Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» obesity
obesity
Amid Wegovy's supply woes, Novo Nordisk sees surging demand for its original obesity drug Saxenda
Fierce Pharma
Thu, 08/4/22 - 11:05 am
Novo Nordisk
obesity
drug manufacturing
Wegovy
Novo Nordisk, Eli Lilly poised to divvy up obesity market that could be worth $50B in 2030: analysts
Fierce Pharma
Sun, 07/17/22 - 11:07 pm
Eli Lilly
Novo Nordisk
obesity
A decade after its first approval, FDA expands weight loss pill's label for use in adolescents
Endpoints
Tue, 06/28/22 - 10:44 am
Vivus
Qsymia
teens
FDA
obesity
Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data
Fierce Biotech
Wed, 06/8/22 - 10:34 am
Innovent
Eli Lilly
Novo Nordisk
obesity
clinical trials
mazdutide
Weigh to Go: Gelesis Boasts Positive Results for Weight Loss Treatment
BioSpace
Thu, 05/5/22 - 10:24 am
PureTech Health
Gelesis Holdings
clinical trials
GS200
diabetes
obesity
weight loss
Novo's Wegovy supply rebound on track for later this year as demand stays strong
Fierce Pharma
Mon, 05/2/22 - 11:04 am
Novo Nordisk
obesity
Wegovy
Lilly's tirzepatide clears high bar set by Novo's Wegovy in obesity
Fierce Biotech
Thu, 04/28/22 - 10:53 am
Eli Lilly
tirzepatide
obesity
Wegovy
Novo Nordisk
Study: PD-L1 may have Application in Obesity Treatment
BioSpace
Thu, 03/10/22 - 11:04 am
PD-L1
obesity
Novo Nordisk, citing strong Wegovy demand, doubles 2025 sales target for obesity franchise
Fierce Pharma
Thu, 03/3/22 - 10:54 am
Novo Nordisk
obesity
Wegovy
Saxenda
Novo Nordisk gets NICE okay for obesity drug Wegovy
Pharmaforum
Tue, 02/8/22 - 09:55 am
Novo Nordisk
Wegovy
UK
NICE
obesity
Pfizer accuses former employees of 'treachery' in stealing trade secrets to form Regor Therapeutics
Fierce Biotech
Thu, 02/3/22 - 10:34 am
Pfizer
diabetes
obesity
legal
trade secrets
Novo Nordisk's Wegovy, hamstrung by Catalent FDA write-up, could correct course by mid-2022: analysts
Fierce Pharma
Thu, 01/27/22 - 10:47 am
Novo Nordisk
Catalent
Wegovy
obesity
FDA
Novo Nordisk moves to strengthen obesity efforts
Pharmaforum
Mon, 01/17/22 - 10:27 am
Novo Nordisk
obesity
EraCal Therapeutics
JPM 2022: Eli Lilly CEO mulls using Novo's double-branding trick on tirzepatide—one obesity, one diabetes
Fierce Pharma
Wed, 01/12/22 - 11:10 am
JPMHC 2022
Eli Lilly
Dave Ricks
tirzepatide
diabetes
obesity
Novo Nordisk's weight loss drug Wegovy to run short amid contract manufacturer hiccup
Fierce Pharma
Mon, 12/20/21 - 10:50 am
Novo Nordisk
Wegovy
obesity
drug manufacturing
drug shortages
Novo Nordisk nears EU approval of obesity drug Wegovy
Pharmaforum
Fri, 11/12/21 - 10:34 am
Novo Nordisk
Wegovy
obesity
Europe
Demand for new obesity drug outstripping supply
Beckers Hospital Review
Wed, 11/3/21 - 11:29 pm
Novo Nordisk
Wegovy
obesity
Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch
Fierce Pharma
Tue, 10/19/21 - 10:50 am
Novo Nordisk
obesity
Wegovy
pharma marketing
drug launches
CVS Health
On a quest to challenge Novo Nordisk in obesity, transpacific startup picks up $70M — and a pair of seasoned execs
Endpoints
Tue, 10/12/21 - 11:43 pm
Sciwind Biosciences
funding
obesity
Novo Nordisk
Altimmune slips after posting 12-week data from Phase 1 trial for weight loss therapy
Seeking Alpha
Tue, 09/28/21 - 11:14 pm
Altimmune
clinical trials
obesity
pemvidutide
Pages
« first
‹ previous
…
10
11
12
13
14
15
16
17
18
…
next ›
last »